Effect of Immunotherapy on sCD23 Levels in Patients Allergic to Hymenoptera Venom

Forman, S. O.; Reddy, Mohan M.; Mazza, David S; Meriney, David; Grieco, Michael H.

doi:10.1016/s1081-1206(10)63321-2

Cited by 3 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study has demonstrated that immunotherapy can decrease serum levels of sCD23 in perennial allergic rhinitis, but the effect of immunotherapy on sCD23 levels in patients allergic to Hymenoptera venom was different, as reported by Forman et al 24 In their study, sCD23 levels in 15 patients were determined before and at variable times during immunotherapy (mean duration, 54 months), and sCD23 levels were found to be unchanged over the course of venom immunotherapy. In addition, their patients had lower mean sCD23 levels when compared with nonatopic controls.…”

Section: Discussionsupporting

confidence: 64%

Decrease of Serum Levels of Soluble CD23 during Immunotherapy in Patients with Perennial Allergic Rhinitis

Tanaka¹,

Ōhashi²,

Nakai³

1999

Ann Otol Rhinol Laryngol

View full text Add to dashboard Cite

There is increasing in vitro evidence that soluble CD23 (sCD23) is capable of potentiating the synthesis of human IgE and is likely involved in the expression of allergic diseases. Our study has aimed at investigating whether serum sCD23 is elevated in patients with perennial allergic rhinitis as compared to nonatopic controls, whether sCD23 in perennial allergic rhinitis fluctuates during the natural course in untreated patients, and whether sCD23 is decreased by immunotherapy. This study included 139 patients with perennial allergic rhinitis due to Dermatophagoides farinae who gave informed consent to participation. They were divided into 2 groups--an untreated group and an immunotherapy group--according to their treatment background. Thirty-one nonallergic, healthy volunteers were included to serve as controls. Symptom scores and serum concentrations of IgE specific to D. farinae and sCD23 were examined twice in each patient: at enrollment (first evaluation) and on a variant time course after enrollment (second evaluation). Serum concentrations of sCD23 were measured by a sandwich enzyme-linked immunosorbent assay. The level of sCD23 in patients with perennial allergic rhinitis was significantly higher than that in nonatopic controls (p < .0001). The level of sCD23 in perennial allergic rhinitis was correlated with the level of specific IgE against D. farinae. The sCD23 level did not fluctuate during the natural course for a span of 2.8 +/- 2.7 years in untreated patients (p = .1337), but was significantly decreased in patients who received immunotherapy for 2.7 +/- 2.2 years (p < .0001). The rate of decrease in sCD23 was significantly correlated with the rate of decrease in specific IgE (rs = .523, p < .0001) and symptom scores (rs = .450, p < .0001). In conclusion, the reduction in sCD23 during immunotherapy is probably related to the decrease in specific IgE and also plays a role in mediating its clinical effect.

show abstract

Section: Discussionsupporting

confidence: 64%

Decrease of Serum Levels of Soluble CD23 during Immunotherapy in Patients with Perennial Allergic Rhinitis

Tanaka¹,

Ōhashi²,

Nakai³

1999

Ann Otol Rhinol Laryngol

View full text Add to dashboard Cite

show abstract

“…Our study has demonstrated that immunotherapy can decrease a seasonal increase in sCD23 in seasonal allergic rhinitis, but the effect of immunotherapy on sCD23 levels in patients allergic to Hymenoptera venom was recently reported by Forman et a1. 22 In their study, sCD23 levels in 15 patients were determined before and at variable time courses during immunotherapy (mean duration, 54 months), and sCD23 levels were found to be unchanged over the course of venom immunotherapy. In addition, their patients had lower mean sCD23 levels when compared with nonatopic controls.…”

Section: Discussionmentioning

confidence: 99%

Immunotherapy Decreases Seasonal Rise in Serum‐Soluble CD23 in Seasonal Allergic Rhinitis

et al. 1998

View full text Add to dashboard Cite

There is increasing in vitro evidence that soluble CD23 (sCD23) is capable of potentiating IgE synthesis, but the in vivo physiologic significance remains to be established. This study investigated the seasonal changes in sCD23 in patients with seasonal allergic rhinitis. It included 112 adult patients with seasonal allergic rhinitis due to Japanese cedar pollens and 20 nonatopic healthy volunteers. The 64 patients of the pharmacotherapy group were treated with nonsedating antihistamine tablets alone throughout the pollen season and the remaining 48 patients of the immunotherapy group continued to be treated with immunotherapy. Serum concentrations of sCD23 were measured in each patient, before and during the pollen season of 1996, by a sandwich enzyme-linked immunosorbent assay. The serum levels of sCD23 in the pharmacotherapy group before the pollen season were significantly higher than those in the nonatopic group (P = .0130) and those in the immunotherapy group (P = .0316). Seasonal increase in sCD23 was significant in the pharmacotherapy group, irrespective of the clinical response (P < .0001). By contrast, sCD23 was not significantly increased in the good responders to immunotherapy (P = .1826), but was significantly increased in the poor responders to immunotherapy (P = .0052). A significant correlation between seasonal increase in rate in specific IgE and seasonal increase in rate in sCD23 was confirmed in both the pharmacotherapy group (rs = 0.321, P = .0107) and the immunotherapy group (rs = 0.474, P = .0012). In conclusion, seasonal rise in sCD23 is associated with and is probably involved in seasonal rise in specific IgE in patients with seasonal allergic rhinitis, and successful immunotherapy is capable of blunting seasonal increase in sCD23, thus resulting in attenuation of seasonal increase in specific IgE and clinical benefits during the pollen season.

show abstract

“… 19 , 39 However, there are also papers showing negative associations between sCD23 levels and atopy. 40 , 41 One potential explanation could be different isoforms having different functional implications, for example, monomers inhibit IgE synthesis while tetramers upregulate IgE synthesis. 18 This could also affect antigen‐specific IgE synthesis.…”

Section: Discussionmentioning

confidence: 99%

“…There are reports showing increased sCD23 serum levels of allergic rhinitis patients monosensitized to grass pollen during the symptomatic period and higher sCD23 levels in asthmatic patients compared to healthy controls 19,39 . However, there are also papers showing negative associations between sCD23 levels and atopy 40,41 . One potential explanation could be different isoforms having different functional implications, for example, monomers inhibit IgE synthesis while tetramers upregulate IgE synthesis 18 .…”

Section: Discussionmentioning

confidence: 99%

Soluble IgE‐binding factors in the serum of food‐allergic patients: Possible pathophysiological role of soluble FcεRI as protective factor

Steinert

Moñino-Romero

Butze

et al. 2023

Clinical & Translational All

View full text Add to dashboard Cite

Background IgE‐mediated food allergy is the result of an aberrant immune response involving the interaction of a food allergen with its specific IgE bound to FcɛRI, the high affinity IgE receptor, on mast cells. Allergen‐specific IgE also binds to soluble binding factors, but, their expression and role in food allergy is not well characterized. Here, we assess the prevalence and relevance of soluble IgE binding factors in food allergy and tolerance. Methods We measured serum levels of four IgE binding factors, that is, galectin‐3, galectin‐9, soluble FcɛRI (sFcεRI) and soluble CD23 (sCD23) in 67 adults sensitized to peanut or hazelnut and sFcɛRI in 29 children sensitized to hen's egg. Adults without food allergen sensitization ( n = 17) served as healthy controls. We compared serum levels of patients and controls and assessed them, in the former, for links to clinical features including allergy and tolerance. Results Serum levels of sFcɛRI and sCD23, but not galectin‐3 and galectin‐9, significantly differ in food‐sensitized patients as compared to healthy controls. A subgroup (28%) of peanut and hazelnut allergic patients had elevated sFcεRI levels, that were associated with higher total and specific IgE levels. Furthermore, sFcεRI levels were significantly higher in tolerant subjects compared to allergics. Among hazelnut allergic patients, those with high sFcεRI levels tolerated the highest protein amounts in the oral food challenge. Conclusion sFcɛRI but not sCD23, galectin‐3 and galectin‐9 might play a role in the pathophysiology of food allergy. Its functional role or use as biomarker should be assessed in further studies.

show abstract

Effect of Immunotherapy on sCD23 Levels in Patients Allergic to Hymenoptera Venom

Cited by 3 publications

References 6 publications

Decrease of Serum Levels of Soluble CD23 during Immunotherapy in Patients with Perennial Allergic Rhinitis

Decrease of Serum Levels of Soluble CD23 during Immunotherapy in Patients with Perennial Allergic Rhinitis

Immunotherapy Decreases Seasonal Rise in Serum‐Soluble CD23 in Seasonal Allergic Rhinitis

Soluble IgE‐binding factors in the serum of food‐allergic patients: Possible pathophysiological role of soluble FcεRI as protective factor

Contact Info

Product

Resources

About